Researchers reported blocking the GPNMB protein responsible for spreading toxic immune cells in neural tissues.
Officials said the clinical trial mapped inflammatory pathways that accelerate neurodegenerative progression.
Targeting GPNMB reduced immune-mediated neural damage in study models.
Scientists said the approach requires further human trials before therapeutic application. No further schedule changes were announced.
Researchers blocked the GPNMB protein implicated in spreading toxic immune cells in Parkinson’s brain tissue. No expanded comment was offered beyond published materials.
Named entities in source reporting include GPNMB, Parkinson’s researchers.
Available filings identify the parties and venues involved without additional unsourced claims.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/parkinsons-protein-block-32